Fresenius Medical Care Names Shervin Korangy CEO, Succeeding Helen Giza

PR Newswire··DEUS·Read original
2▲0 ▼0Impact / 5
Summary · why it matters

Fresenius Medical Care announced that Shervin J. Korangy, 51, will become Chief Executive Officer and Chair of the Management Board effective October 12, 2026, succeeding Helen Giza, 58, who has served as CEO for four years after three years as CFO. The Supervisory Board unanimously appointed Korangy, who has been a member of that board since 2023 and most recently served as CEO of U.S.-headquartered BVI Medical, where he transformed the business into a global leader in surgical eye care. Giza's tenure included the FME25+ transformation program, which reduced the company's cost base by around EUR 1.2 billion and reshaped its organization and processes. In connection with his appointment, Korangy has resigned from FME's Supervisory Board, and the board has identified Ann Custin, who has almost 40 years of management experience in the global healthcare sector, as a highly qualified successor, with court proceedings to appoint her until the end of the current term to be initiated in due course. Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, serves around 4.5 million dialysis patients worldwide through a network of 3,513 dialysis clinics and employs almost 110,000 people.

Impact on assets 1

Health Care▲

Theme Impact 1

Off-coverage companies 1

BVI Medicali
Private± Mixedrelevance

Related news

Germany
2

Fresenius Medical Care Appoints Shervin Korangy as CEO

Fresenius Medical Care has appointed Shervin Korangy as CEO and board chairman, effective Oct. 12, succeeding Helen Giza. Korangy most recently served as CEO of BVI Medical, a manufacturer of ophthalmic equipment, and has sat on Fresenius' Supervisory Board since 2023. He has resigned from that Supervisory Board seat and will be replaced there by Ann Custin. Fresenius shares are off ~7% in Wednesday morning trading.
About megatrends
Aging Population › Dialysis & Renal Care Talent
FME.XETRA · Capital · Negative Fresenius Medical Care appoints a new CEO, succeeding Helen Giza, and shares fell ~7% on the leadership change.
Read original ↗
Seeking Alpha·3dRead more →
Thailand
▲

KTMS expects better Q4 2026 results as new branches lift utilisation rate to no less than 80%

KT Medical Service Public Company Limited, or KTMS, expects its operating performance in the fourth quarter of 2026 to improve as new branches gradually come into service. Chief Executive Officer Kanjana Pongpattanadecha told Than Hoon that branches already open have a utilisation rate of no less than 80% of total service space, reflecting demand for dialysis services that remains high. The company currently holds contracts for 11 branches and aims to open them gradually in line with its plan, with the timing of each opening depending on the government licensing process, which now takes about 120 days, up from roughly 90 days previously. This delays revenue recognition from new branches relative to plan, but it is a shift in timing rather than a loss of revenue. For the first half of 2026, the company reported revenue from the sale of goods and services of 350.63 million baht, up 7.77 million baht, or 2.27%, from the same period a year earlier, with net profit of 12.99 million baht. In the second quarter of 2026, revenue was 175.96 million baht, up 1.41% from the same period a year earlier, with net profit of 5.69 million baht.
About megatrends
Aging Population › Dialysis & Renal Care ▲Demand
KTMS.BK · Demand · Positive New branches opening with utilisation of at least 80% reflect high demand for dialysis services, expected to lift Q4 2026 results.
KTMS.BK · Regulation · Negative Government licensing now takes about 120 days versus 90, delaying revenue recognition from new branches relative to plan.
Read original ↗
Thunhoon·6dRead more →
Thailand
▲4

GWM25 launches ready-to-drink protein powder, targets 10 dialysis centres per year from 2027

Grace Water Med Public Company Limited, or GWM25, a leader in the development and distribution of comprehensive haemodialysis products, is preparing to launch a sachet-style ready-to-drink protein product in the fourth quarter of this year, while continuing to expand its kidney health business. Thongchai Pami, Chief Executive Officer, disclosed after presenting the company's operating results to investors at Opportunity Day that in the first six months of 2026 the company recorded total revenue of 104.68 million baht, an increase of 8.91 million baht, or 9.30%, from 95.77 million baht in the same period last year. Total liabilities fell to 78.86 million baht, while shareholders' equity rose to 64.16 million baht, bringing the debt-to-equity ratio down from 1.28 times to 1.23 times. The company currently has dialysate production capacity of approximately 240,000 gallons per month and has expanded its One-stop Service Solutions, covering everything from consultation on setting up dialysis centres, design and equipment procurement to the recruitment and training of personnel. For its second-half plan, the company is still negotiating with new partners to extend the business in several areas and will expand all products onto every online platform. The company is confident it can sustain growth in 2026, will open one dialysis centre, and will expand by 10 centres per year starting in 2027, in support of its plan to prepare for a listing on the mai stock exchange by 2028.
About megatrends
Aging Population › Dialysis & Renal Care ▲Supply
Read original ↗
Money & Banking·9dRead more →
ChinaGermany
▼

Fresenius Medical Care Reshapes China Portfolio, Exits Peritoneal Dialysis

Fresenius Medical Care AG & Co. FMS is refining its China commercial strategy to prioritize advanced in-center dialysis and critical-care technologies while discontinuing local production and sales of the 4008A hemodialysis system and exiting its China peritoneal dialysis business. China contributes approximately 6-7% of the company's Care Enablement operating segment revenues, and the company will emphasize the high-volume hemodiafiltration-enabled 5008S CAREsystem, multiFiltratePRO and other advanced dialysis technologies, supported by its local manufacturing footprint and China Design Center. The portfolio actions are expected to result in approximately €110 million of one-time costs, primarily impairment charges, scrappage and termination costs, recognized as a special item in the third quarter of 2026, and FMS does not expect the changes to significantly affect the future revenue outlook for its China Care Enablement business. The company also appointed Rex Liu as market general manager, and Joe Turk, CEO of the Care Enablement operating segment, said the refined portfolio and strategy will strengthen its ability to compete and grow in China. FMS stock has gained 1.1% since the announcement on Friday and has a market capitalization of $12.19 billion.
About megatrends
Aging Population › Dialysis & Renal Care ▼Competition
FME.XETRA · Capital · Neutral Fresenius Medical Care exits China peritoneal dialysis and discontinues 4008A production, taking ~€110M one-time impairment/termination costs as a special item.
Read original ↗
Zacks Investment Research·11dRead more →
ChinaGermany

Fresenius Medical Care Refines China Strategy, Exits Peritoneal Dialysis Business

Fresenius Medical Care announced refinements to its China commercial strategy aimed at long-term growth and market leadership through a more localized portfolio and focused go-to-market approach. China represents approximately 6-7% of the company's Care Enablement operating segment revenues, and the company has operated there for more than two decades. As part of the changes, Fresenius Medical Care appointed Rex Liu as market General Manager and will increasingly focus on innovative technologies for in-center dialysis and critical care, including the high-volume hemodiafiltration-enabled 5008S CAREsystem and multiFiltratePRO. The company will discontinue local production and sales of the 4008A hemodialysis system and exit its China peritoneal dialysis business while maintaining existing obligations in the market. The portfolio actions are expected to result in one-time costs of approximately €110 million, primarily impairment charges, scrappage and termination costs, treated as a special item and recognized in the third quarter of 2026, with no meaningful impact expected on the future revenue outlook for Care Enablement's China business.
About megatrends
Aging Population › Dialysis & Renal Care Competition
FME.XETRA · Regulation · Neutral Refines China strategy with localized portfolio and exits peritoneal dialysis business, incurring ~€110M one-time costs but no meaningful revenue impact.
Read original ↗
PR Newswire·16dRead more →
Thailand
▲4

KTMS Targets 800 Million Baht Revenue, Opens 11 New Dialysis Units

KTMS has announced a total revenue target of 800 million baht for 2026, driven by the rising trend of kidney disease patients boosting demand for hemodialysis. The company plans to open 11 new dialysis units in the second half of 2026, with 4 units in the third quarter and 7 more in preparation. It will also install an additional 36-64 dialysis machines, increasing from the current 541, to serve over 120,000 dialysis patients nationwide. Ms. Kanjana Pongpatthanadet, Chief Executive Officer, revealed that Thailand has approximately 8 million people at risk of chronic kidney disease, with about 120,000 patients requiring hemodialysis. Hemodialysis is the primary treatment method chosen by 80% of patients. In the first half of 2026, the company reported revenue of 350.63 million baht, up 2.27% from the same period last year, and a net profit of 12.99 million baht.
About megatrends
Aging Population › Dialysis & Renal Care ▲Demand
KTMS.BK · Demand · Positive Rising kidney disease patients boost demand for hemodialysis, supporting revenue target and expansion.
Read original ↗
thunhoon.com·31dRead more →